Extending FDA-approved cancer drug indications requires high patient numbers, study finds Post author: Post published:September 29, 2023 Post category:uncategorized Number of patient participants needed for secondary approval of a new cancer drug. You Might Also Like Myopenia identified as key contributor to muscle loss in rheumatoid arthritis July 11, 2025 Study reveals how long COVID can affect brain function through vascular disruption February 26, 2024 Women experience greater weight loss with tirzepatide compared to men September 11, 2024